[
    [
        {
            "time": "",
            "original_text": "恒瑞、科伦、中国生物制药？谁会成为注射剂一致性评价的赢家？",
            "features": {
                "keywords": [
                    "恒瑞",
                    "科伦",
                    "中国生物制药",
                    "注射剂",
                    "一致性评价"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞、科伦、中国生物制药？谁会成为注射剂一致性评价的赢家？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "重销售轻研发，警惕这些畸形发展的药企",
            "features": {
                "keywords": [
                    "销售",
                    "研发",
                    "畸形发展",
                    "药企"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "重销售轻研发，警惕这些畸形发展的药企",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-05",
            "original_text": "【国信医药】继续紧握龙头，重视IVD需求弹性（5月投资策略）",
            "features": {
                "keywords": [
                    "国信医药",
                    "龙头",
                    "IVD",
                    "需求弹性",
                    "投资策略"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "IVD"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国信医药】继续紧握龙头，重视IVD需求弹性（5月投资策略）",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "巨丰原创：后疫情时代 低估值医药股受资金关注 两主线可以加码",
            "features": {
                "keywords": [
                    "后疫情时代",
                    "低估值",
                    "医药股",
                    "资金关注",
                    "两主线",
                    "加码"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "巨丰原创：后疫情时代 低估值医药股受资金关注 两主线可以加码",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]